TriGenix done in by a string of bad luck

Noteworthy

TriGenix Inc. is planning on closing its doors, a victim both of D. Blech's financial problems and the failure of Celtrix Pharmaceuticals Inc.'s Phase III BetaKine trial to show efficacy in macular holes...